{"id":71388,"date":"2026-05-20T08:30:59","date_gmt":"2026-05-20T08:30:59","guid":{"rendered":"https:\/\/medsbase.com\/ara-290\/"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"ara-290","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/ara-290\/","title":{"rendered":"ARA-290 (Cibinetide)"},"content":{"rendered":"

<\/p>\n

\n

Rychl\u00e1 odpov\u011b\u010f \u2014 Co je ARA-290?<\/h3>\n

ARA-290<\/strong> (cibinetide; Helix B Surface Peptide, HBSP) je 11-aminokyselinov\u00fd syntetick\u00fd peptid odvozen\u00fd od helixu B erythropoietinu (EPO). Navr\u017een\u00fd Brines & Cerami k odd\u011blen\u00ed cytoprotektivn\u00edch \u00fa\u010dink\u016f EPO od jeho erytropoetick\u00fdch \u00fa\u010dink\u016f, ARA-290 se v\u00e1\u017ee na innate repair receptor (IRR) \u2014 heterokomplex EPO receptoru a beta-common receptoru (CD131) \u2014 a spou\u0161t\u00ed protiz\u00e1n\u011btlivou, antiapoptotickou a tk\u00e1\u0148ov\u011b repara\u010dn\u00ed signalizaci bez zvy\u0161ov\u00e1n\u00ed masy \u010derven\u00fdch krvinek. Vyvinut\u00fd spole\u010dnost\u00ed Araim Pharmaceuticals; s orphan ozna\u010den\u00edm pro sarkoid\u00f3zou asociovanou neuropatii tenk\u00fdch vl\u00e1ken. Dod\u00e1v\u00e1n v 10 mg lyofilizovan\u00fdch lahvi\u010dk\u00e1ch pouze pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n

Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00e9 lyofilizovan\u00e9 peptidy \u00b7 HPLC \u010distota \u226599% (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1,400+ ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifikace<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS \u010d\u00edslo<\/strong><\/td>\n1208243-50-8 (cibinetide)<\/td>\n<\/tr>\n
Typ<\/strong><\/td>\nNeerytropoetick\u00fd 11-aminokyselinov\u00fd syntetick\u00fd peptid odvozen\u00fd z helixu B lidsk\u00e9ho erytropoetinu (Helix B Surface Peptide, HBSP); agonista vrozen\u00e9ho reparativn\u00edho receptoru (IRR); v\u00fdvojov\u00e9 k\u00f3dy ARA-290 \/ cibinetid (Araim Pharmaceuticals)<\/td>\n<\/tr>\n
item2<\/strong><\/td>\nC51<\/sub>H84<\/sub>N16<\/sub>O21<\/sub><\/td>\n<\/tr>\n
item7<\/strong><\/td>\n~1 257,4 Da<\/td>\n<\/tr>\n
item9<\/strong><\/td>\nH-pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH (pyrEEQLERALNSS) \u2014 line\u00e1rn\u00ed 11-\u010dlenn\u00e1 sekvence odpov\u00eddaj\u00edc\u00ed vodou exponovan\u00e9 plo\u0161e helixu B lidsk\u00e9ho erytropoetinu. N-koncov\u00fd glutamin spont\u00e1nn\u011b cyklizuje na pyroglutam\u00e1t (v souladu s publikovanou molekulovou hmotnost\u00ed 1 257,4 Da). C-konec je voln\u00e1 kyselina; \u017e\u00e1dn\u00fd disulfidov\u00fd m\u016fstek, \u017e\u00e1dn\u00e1 acylace mastn\u00fdmi kyselinami, \u017e\u00e1dn\u00e1 PEGylace.<\/td>\n<\/tr>\n
item11<\/strong><\/td>\nLyofilizovan\u00fd pr\u00e1\u0161ek (b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd)<\/td>\n<\/tr>\n
item13<\/strong><\/td>\n\u226599% (HPLC ov\u011b\u0159eno, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n
Skladov\u00e1n\u00ed<\/strong><\/td>\nLyofilizovan\u00fd: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00fd: 2\u20138 \u00b0C, pou\u017e\u00edt do ~14\u201328 dn\u016f. Chr\u00e1nit p\u0159ed sv\u011btlem. Vyvarovat se opakovan\u00e9ho zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed rekonstituovan\u00e9ho roztoku.<\/td>\n<\/tr>\n
Rozpustnost<\/strong><\/td>\nBakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda. Vysoce rozpustn\u00fd; nemodifikovan\u00fd 11-mer se rychle rozpou\u0161t\u00ed p\u0159i jemn\u00e9m prom\u00edch\u00e1n\u00ed.<\/td>\n<\/tr>\n
Pouze pro v\u00fdzkum<\/strong><\/td>\nPouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

Co je ARA-290?<\/h2>\n

ARA-290<\/strong> (cibinetid) je 11-aminokyselinov\u00fd line\u00e1rn\u00ed syntetick\u00fd peptid odpov\u00eddaj\u00edc\u00ed vodou exponovan\u00e9 plo\u0161e helixu B lidsk\u00e9ho erytropoetinu (EPO) \u2014 oblasti molekuly EPO, kter\u00e1 se nepod\u00edl\u00ed na vazb\u011b na klasick\u00fd homodimern\u00ed receptor EPO (EPOR2<\/sub>) zodpov\u011bdn\u00fd za tvorbu \u010derven\u00fdch krvinek. ARA-290 byl racion\u00e1ln\u011b navr\u017een Michaelem Brinesem a Anthonym Ceramim ve spole\u010dnosti Araim Pharmaceuticals za \u00fa\u010delem odd\u011blen\u00ed dvou farmakologicky odli\u0161n\u00fdch aktivit EPO, kter\u00e9 byly historicky spojeny v jedn\u00e9 molekule: erytropo\u00e9za<\/strong> (efekt zvy\u0161uj\u00edc\u00ed hematokrit, kter\u00fd omezuje pou\u017eit\u00ed EPO jako tk\u00e1\u0148ov\u011b protektivn\u00edho \u010dinidla kv\u016fli riziku tromboembolie) a ochrana tk\u00e1n\u00ed<\/strong> (protiz\u00e1n\u011btliv\u00e9, anti-apoptotick\u00e9 a reparaci podporuj\u00edc\u00ed \u00fa\u010dinky zprost\u0159edkovan\u00e9 odli\u0161n\u00fdm heteromern\u00edm receptorem).<\/p>\n

Omezen\u00edm peptidov\u00e9 sekvence na povrch helixu B si ARA-290 zachov\u00e1v\u00e1 afinitu k vrozen\u00e9mu reparativn\u00edmu receptoru (IRR)<\/strong> \u2014 heterokomplexu slo\u017een\u00e9mu z podjednotky receptoru EPO (EPOR) a beta-spole\u010dn\u00e9ho receptoru (\u03b2cR, CD131; sd\u00edlen\u00e9 signaliza\u010dn\u00ed podjednotky receptor\u016f GM-CSF, IL-3 a IL-5) \u2014 z\u00e1rove\u0148 ztr\u00e1c\u00ed schopnost vazby na EPOR.2<\/sub> homodimer zodpov\u011bdn\u00fd za erytropo\u00e9zu. \u010cist\u00fdm \u00fa\u010dinkem je peptid, kter\u00fd vyvol\u00e1v\u00e1 cytoprotektivn\u00ed, protiz\u00e1n\u011btliv\u00e9 a neuroprotektivn\u00ed \u00fa\u010dinky EPO v tk\u00e1n\u00edch bez zv\u00fd\u0161en\u00ed hematokritu nebo rizik tromboembolick\u00fdch a hypertenzn\u00edch komplikac\u00ed, kter\u00e9 limituj\u00ed terapeutick\u00e9 pou\u017eit\u00ed EPO.<\/p>\n

ARA-290 m\u00e1 kr\u00e1tk\u00fd plazmatick\u00fd polo\u010das p\u0159ibli\u017en\u011b 2 minuty \u2014 molekula je rychle eliminov\u00e1na \u2014 ale biologick\u00fd \u00fa\u010dinek p\u0159etrv\u00e1v\u00e1 24\u201372 hodin d\u00edky n\u00e1sledn\u00e9 aktivaci cytoprotektivn\u00edch sign\u00e1ln\u00edch kask\u00e1d (JAK2\/STAT3, PI3K\/Akt, upregulace anti-apoptotick\u00e9 rodiny Bcl-2). Tento farmakokinetick\u00fd profil je charakteristick\u00fd pro peptidy spou\u0161t\u011bj\u00edc\u00ed receptory, kde d\u00e9lka \u00fa\u010dinku je d\u00e1na kinetikou sign\u00e1ln\u00ed kask\u00e1dy sp\u00ed\u0161e ne\u017e trval\u00fdmi hladinami v plazm\u011b. ARA-290 z\u00edskal status sirot\u010d\u00edho l\u00e9ku<\/strong> ve Spojen\u00fdch st\u00e1tech a Evropsk\u00e9 unii pro sarkoid\u00f3zou asociovanou neuropatii mal\u00fdch vl\u00e1ken a byl hodnocen v n\u011bkolika klinick\u00fdch studi\u00edch f\u00e1ze 2 u diabetick\u00e9 neuropatie a neuropatick\u00e9 bolesti spojen\u00e9 se sarkoid\u00f3zou. Nen\u00ed FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> schv\u00e1len pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed FDA, EMA, MHRA ani \u017e\u00e1dnou jinou v\u00fdznamnou regula\u010dn\u00ed autoritou. V\u00fdzkumn\u00fd ARA-290 prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro lidsk\u00e9 ani veterin\u00e1rn\u00ed pod\u00e1v\u00e1n\u00ed.<\/p>\n

Mechanismus \u00fa\u010dinku \u2014 agonismus vrozen\u00e9ho reparativn\u00edho receptoru bez erytropo\u00e9zy<\/h2>\n

Co \u010din\u00ed ARA-290 farmakologicky v\u00fdjime\u010dn\u00fdm, je jeho schopnost aktivovat cytoprotektivn\u00ed v\u011btev signalizace erytropoetinu, zat\u00edmco obch\u00e1z\u00ed v\u011btev erytropoetickou. Ve publikovan\u00e9m v\u00fdzkumu jsou dokumentov\u00e1ny t\u0159i mechanismy:<\/p>\n